Lucent Diagnostics

The LucentAD p-Tau 217 test is a breakthrough aid in Alzheimer's Disease diagnosis. With a sensitivity of 90.3%, specificity of 91.3%, and accuracy over 90%, the LucentAD p-Tau 217 test offers unparalleled diagnostic utility. Reach out today to learn more. https://bit.ly/4dCkrwP #Alzheimers #LucentAD #pTau217Test #Diagnostics #ClinicalUtility #DiagnosticUtility

🧠 Exciting advancements in Alzheimer’s diagnostics could revolutionize preventive medicine. With the potential for accurate blood tests, early diagnosis becomes accessible on a large scale. Discover how routine blood tests are poised to transform Alzheimer’s diagnosis and treatment initiation. Read more from Scientific American and the Davos Alzheimer's Collaborative: https://bit.ly/4bu4ZkL #Alzheimers #EndALZ #PreventiveCare

Join us in raising awareness about Alzheimer’s disease, the leading cause of dementia affecting millions worldwide. Alzheimer’s disease, responsible for 60-80% of dementia cases, presents with memory loss and cognitive challenges impacting daily life. To learn more about Alzheimer’s disease and access valuable resources, visit the Alzheimer’s Association – What is Alzheimer’s page. https://bit.ly/2QPnsQe Together, let’s support those affected and work towards a brighter future. #AlzheimersAwareness #Dementia #EndAlz

#DYK training and clinical validation for the LucentAD p-Tau 217 were performed in a combined cohort of over 500 subjects? Participants had a range of cognitive status, including mild cognitive impairment and early Alzheimer’s disease. The validation compared the test results to amyloid status determined by CSF biomarker testing and amyloid PET imaging. The LucentAD p-Tau 217 test had an overall accuracy exceeding 90%, meeting the strict requirements set forth in the most recent Alzheimer’s Association Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease. Learn more about the p-Tau 217 blood-based test from Lucent Diagnostics: https://bit.ly/3IWGPmG #BloodBiomarkers #Alzheimers #CognitiveDecline

Understanding your LucentAD test results is a key step in Alzheimer's diagnostics. 🧠 The lab report, including your p-Tau level, is carefully assessed against our clinical cutoff for Alzheimer's pathology likelihood. Your healthcare provider will guide you through the report, answer questions, and discuss the best next steps for your care. Lucent Diagnostics is committed to providing clarity and support in the journey toward cognitive health. #LucentAD #AlzheimersDiagnostics #Healthcare

Alzheimer's therapies are entering an exciting new era with the arrival of medications that target the underlying causes of the disease. However, for these promising treatments to reach their full potential, doctors need noninvasive and inexpensive methods to aid in the diagnoses of patients. Blood-based biomarkers are offering a new path towards increasing availability of diagnostics aids. In recent years, diagnostic tools measuring blood biomarkers have grown in sensitivity and accuracy. One example is the p-Tau 217 blood biomarker which is over 90% accurate at detecting amyloid protein clumps in the brain — a hallmark of Alzheimer's — and meets the accuracy standards recently revised by the Alzheimer's Association® for using a biomarker test as a diagnostic tool. To learn more about Lucent Diagnostic’s p-Tau 217 blood test, read the full feature on Nature Portfolio: https://lnkd.in/dRiPCEpn

🧠 Recent advancements in blood-based biomarkers for Alzheimer’s Disease offer a less invasive approach than traditional methods. New literature research published in a special issue of Advances in Biomarkers for Neurodegenerative Diseases, covering 2018 to 2023, sheds light on the complex relationship between biomarkers like T-Tau, p-Tau, NfL, and GFAP and cognitive performance. Notably, p-Tau emerges with stronger associations, hinting at its potential to aid cognitive assessments. https://bit.ly/4at2YEQ #AlzheimersResearch #BloodBiomarkers #CognitiveHealth

#DYK: Quanterix is expanding access to high-accuracy, non-invasive Alzheimer's disease testing. Our collaborations with multiple health systems mean greater accessibility for patients across 18 states and benefiting approximately 21 million patients in their networks. https://bit.ly/3ICP9Ie #Alzheimers #PatientHealth #Healthcare

Lucent Diagnostics is proud to partner with Neurocode Labs, Inc. and support the launch of its clinical novel pTau217 blood test for Alzheimer’s disease (AD) — a test powered by ultrasensitive Simoa® technology. P-Tau 217 has surfaced as a leading biomarker for AD pathology, recognized by the Alzheimer’s Association working group diagnostic criteria as the sole plasma biomarker suitable for precise amyloid pathology diagnosis. Significant advancements in blood-based biomarkers for AD research and diagnostics have largely been driven by ultrasensitive detection technology such as Quanterix’s Simoa, the same technology that will power Neurocode’s newest pTau217 blood test. The immunoassays developed using Simoa enable the detection of numerous blood-based biomarkers that are significant for Alzheimer’s diagnosis. Read through the full announcement from Neurocode: https://bit.ly/3TlH4NX

Lucent Diagnostics is proud to partner with Neurocode Labs, Inc. and support the launch of its clinical novel pTau217 blood test for Alzheimer’s disease (AD) — a test powered by ultrasensitive Simoa® technology. P-Tau 217 has surfaced as a leading biomarker for AD pathology, recognized by the Alzheimer’s Association working group diagnostic criteria as the sole plasma biomarker suitable for precise amyloid pathology diagnosis. Significant advancements in blood-based biomarkers for AD research and diagnostics have largely been driven by ultrasensitive detection technology such as Quanterix’s Simoa, the same technology that will power Neurocode’s newest pTau217 blood test. The immunoassays developed using Simoa enable the detection of numerous blood-based biomarkers that are significant for Alzheimer’s diagnosis. Read through the full announcement from Neurocode: https://bit.ly/3TlH4NX